With the recent discoveries of immunologic pathways leading to psoriasis, clinicians are likely to discount older general immunosuppressive agents in favor of newer larger molecules like biologics that provide better targeted therapy.
The goal of this activity is to educate pharmacists and pharmacy technicians about pharmacist interventions in improving the quality of life for patients with psoriasis and psoriatic arthritis. Readers will also gain knowledge about available options for treatment, adverse
effects, risks, and benefits.
There’s good evidence to suggest dermatologists who assess psoriasis patients should look beyond the plaques on the skin and consider not just the increased risk to the joints, but also the heart, mind and more.
Researchers at the University of Würzburg in Bavaria, Germany, are focusing their psoriasis research on a cell type that has received little attention in connection with the skin disease: B lymphocytes.
A new study suggests that insurance coverage of biologics for psoriasis is becoming more challenging. The need for prior authorization is increasing, as are the average time from prior authorization submission to coverage decisions and prior authorization denial rates.